Skip to main content
NOVELIX PHARMACEUTICALS LIMITED logo

NOVELIX PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 536565 ISIN · INE314I01036 LEI · 8945002HROSD4VUIYY08 BSE.NS Manufacturing
Open in API
Filings indexed 19 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country IN India
Listing BSE.NS 536565

About NOVELIX PHARMACEUTICALS LIMITED

https://novelixpharma.com/

Novelix Pharmaceuticals Limited specializes in the research, development, and large-scale manufacturing of pharmaceutical formulations and active ingredients. The company’s portfolio encompasses a broad spectrum of therapeutic segments, including cardiology, gastroenterology, and metabolic health. It focuses on the production of high-quality generic medications, utilizing sophisticated chemical synthesis and formulation technologies to ensure bioequivalence and safety. Core competencies include the development of diverse dosage forms such as oral solids, liquids, and parenteral preparations. By integrating rigorous quality management systems and advanced analytical testing, the organization maintains a commitment to delivering standardized healthcare solutions aimed at improving clinical outcomes across various medical disciplines.

Recent filings

Filing Released Lang Actions
Intimation of production scale up agreement.
Regulatory Filings Classification · 76% confidence The document is an intimation under Regulation 30/30A of the SEBI (LODR) Regulations, submitted to the stock exchange to disclose a material agreement entered by the company. It is not a full financial report, earnings release, management change announcement, share issue, M&A transaction, or other specific category. It is a routine regulatory disclosure of a corporate event, fitting the fallback category “Regulatory Filings” (RNS).
2026-06-03 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gattu Gnana Prakash & Others
Major Shareholding Notification Classification · 89% confidence The document is a formal stock exchange filing under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. It discloses the allotment and acquisition of equity shares by promoters/PACs following conversion of warrants. It contains detailed pre- and post-acquisition shareholding percentages and the prescribed format under Regulation 29(2). This matches the definition of a Major Shareholding Notification (MRQ), which covers disclosures of significant ownership changes.
2026-06-03 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Vrupparapalli Reddy & Vrupparapalli Pavani
Major Shareholding Notification Classification · 90% confidence The document is a statutory disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (Regulation 29(2)), detailing shareholding changes by promoters through conversion of warrants. It is not a full financial report or a board change announcement, but a regulatory notice of acquisition of equity, fitting the “Major Shareholding Notification” category.
2026-06-03 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Srinidhi Fine- Chemicals Llp & Other
Major Shareholding Notification Classification · 85% confidence The document is a statutory disclosure submitted under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 on change in shareholding by acquirers through conversion of warrants. This is a regulatory notification of a share acquisition event by promoters, matching the “Major Shareholding Notification” category.
2026-06-03 English
Submission of Intimation of Allotment of equity shares to promoters and promoter group.
Director's Dealing Classification · 92% confidence The document is a formal disclosure under Regulation 7(2)(b) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, detailing acquisitions of equity shares by promoters/promoter group. Such filings report insider share transactions by directors or insiders. This matches the definition of a Director’s Dealing report (Code: DIRS).
2026-06-02 English
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Srindhi Fine Chemicals LLP
Major Shareholding Notification Classification · 90% confidence The document is a regulatory disclosure under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, detailing the allotment of shares to promoters and changes in shareholding percentages before and after acquisition. It notifies a substantial acquisition/crossing of shareholding thresholds. This matches the definition of a Major Shareholding Notification (code MRQ).
2026-06-02 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.